Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

- Phase III trials now underway to evaluate vandetanib as second-line NSCLC

treatment in combination with docetaxel -

WILMINGTON, Del., Sept. 20 /PRNewswire/ -- Results published today in the Journal of Clinical Oncology(1) show that the AstraZeneca investigational once-daily oral anti-cancer drug vandetanib (ZACTIMA), in combination with docetaxel, improved progression free survival (PFS) in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

The Phase II trial - Study 6 - compared the combination of vandetanib 100mg or 300mg plus docetaxel to standard docetaxel alone. The trial demonstrated that adding vandetanib to standard docetaxel therapy prolonged median PFS to 18.7 weeks and 17 weeks respectively, compared to 12 weeks with docetaxel alone.(2)

"Given the poor prognosis in advanced non-small cell lung cancer, an increase in time to disease progression can be meaningful to patients," said Study 6 lead author John Heymach, Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Centre . "The results of Study 6 provide encouraging support, and reinforce further investigation with ZACTIMA in combination with chemotherapy in Phase III trials."

Based on these data, AstraZeneca has initiated a Phase III trial, currently underway, to evaluate vandetanib and docetaxel in second-line treatment of non-small cell lung cancer. The ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer), trial is a randomised, double- blind study evaluating vandetanib 100mg in combination with docetaxel vs. docetaxel alone, in patients with locally advanced or metastatic NSCLC after failure of first-line treatment.

The study is recruiting and aims to enroll approximately 1400 patients worldwide at over 250 centers throughout Europe, North America, South America and Asia Pacific. The primary end points of the study are to assess PFS. Response rates and overall Sur
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Orthopedics, Inc., the world leader in PyroCarbon orthopedic ... Modular Total Shoulder System. This newly designed system ... shoulder arthroplasty with one implant system. ... in collaboration with Joseph Abboud, M.D, Phillip Duke, ...
... Calif., Sept. 2 NewCardio (OTC Bulletin Board: ... Vincent Renz, Jr., NewCardio,s President and CEO, purchased 128,000 shares ... two weeks following the Company,s filing of its SEC Form ... 30, 2010. "As discussed on our August ...
Cached Medicine Technology:Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System 2NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... kidney donors enjoy similar longevity and cardiovascular health as ... published in the American Journal of Transplantation . ... considering donation and the transplant professionals caring for them. ... by individuals aged 55 years and older has become ... disease, and heart disease, the removal of a kidney ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
(Date:7/8/2014)... discovered a biomarker that could give expecting mothers and ... predict that a pregnant woman may develop preeclampsia, at ... , Preeclampsia is a cardiovascular disorder generally occurring late ... creating immediate and potentially lifelong risks to both mother ... in the urine, and is typically diagnosed in the ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... Actor Joe Pantoliano,reveals a personal history of ... untreated bipolar disorder, in a guest blog entry, ... on Mental,Illness (NAMI)., Pantoliano,s entry comes during ... days before the opening of his latest film, ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... anxiety, low control doubles recurrent heart attack risk, study finds ... doubles the risk that someone who has had a heart ... finds. , Other studies have shown that workplace stress boosts ... anxieties with recurrent heart attacks and other major events, the ...
... scientists have developed a potentially novel way to fight ... of radiation inside cancer cells, unlike current treatments that ... the outside and cause unwanted side effects. , ... new radiation delivery system proved able to specifically target ...
... 9 The March of,Dimes congratulates Mario R. Capecchi, ... Smithies, D.Phil., FRS, former recipients of the,March of Dimes ... in Physiology or Medicine. The Nobel Committee announced ... of principles for introducing specific gene,modifications in mice by ...
... Oct. 9 Health plans are expecting premium,rate increases ... last,year,s expectation of 8.2%. This is the fourth consecutive ... conducted this survey in September of 2007. The survey,contained ... nationwide. Separately, the survey notes that the East ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: